Table 3 Absolute and relative reduction in lipid levels and lipoprotein particle concentration compared to baseline after 8 weeks treatment

VLDL-C (mg/dl) Total

17.2 ± 7.3

14.7 ± 15.4

26

20.0 ± 12.1

5.2 ± 12.9

7.9

 VLDL1

6.7 ± 4.6

6.1 ± 9.1

26.3

6.5 ± 4.5

3.5 ± 6.6

21.6

 VLDL2 + 3

2.6 ± 1.5

2.8 ± 2.7

20.4

3.6 ± 2.5

0.6 ± 2.3

− 20

 VLDL4 + 5

1.9 ± 1.3

2.2 ± 2.5

40.9

2.9 ± 2.3

0.6 ± 1.7

2.8

IDL-C (mg/dl)

5.7 ± 4.1

10.0 ± 7.9

62.0

9.3 ± 4.7

4.3 ± 6.4

20.7

LDL-C (mg/dl) Total

43.8 ± 21.8

81.6 ± 28.7

65.3

80.7 ± 14.8

22.9 ± 25.1

18.1

 LDL1 + 2

10.4 ± 4.3

9.6 ± 8.5

40.4

11.3 ± 4.6

4.2 ± 5.7

21.2

 LDL3 + 4

7.0 ± 4.9

10.2 ± 9.4

50.3

11.1 ± 4.5

2.4 ± 5.9

− 20.7

 LDL5 + 6

5.0 ± 5.6

21.2 ± 12.7

79.5

17.6 ± 5.9

5.4 ± 7.4

6.6

HDL-C (mg/dl) Total

46.9 ± 8.3

− 2.9 ± 6.5

− 7.6

44.8 ± 8.3

− 0.4 ± 9.0

− 3.4

 HDL1 + 2

10.2 ± 4.4

0.7 ± 3.6

− 2.2

10.5 ± 4.2

0.1 ± 2.6

− 2.7

 HDL3 + 4

12.6 ± 5.4

− 1.9 ± 3.2

− 82.7

11.3 ± 5.3

− 0.6 ± 4.1

27.2

TC (mg/dl)

109.9 ± 27.9

106.0 ± 37.8

48.4

153.7 ± 18.4

35.9 ± 33.7

16.9

VLDL-P (nmol/l)

158.2 ± 56.9

80.2 ± 84.8

19.1

165.5 ± 80.3

17.4 ± 79.5

− 1.2

IDL-P (nmol/l)

37.4 ± 22.1

54.0 ± 45.2

53.3

60.7 ± 28.8

27.8 ± 31.9

24.5

LDL-P (nmol/l) Total

463.6 ± 246.7

1128.9 ± 374.6

71

985.2 ± 203.3

332.5 ± 32.6

21.7

 LDL1 + 2

113.5 ± 40.1

91.4 ± 81.3

38.33

120.4 ± 45

40.5 ± 54.1

14.5

 LDL3 + 4

80.1 ± 52.7

119.8 ± 98.9

57.3

129.5 ± 45

32.5 ± 67.3

− 16.7

 LDL5 + 6

70.9 ± 76.8

304.8 ± 192.1

76.8

246.4 ± 91.8

83.0 ± 99.4

13.3

Lp(a) (nmol/l)

57.5(5.2,72.8)

15.6(8.5,29.5)

21.1

42.6(8.9,62.8)

− 13.9(− 19.2,− 0.3)

− 42.5

ApoB

42.3 ± 14.8

67.5 ± 23.6

60.9

71.5 ± 14.0

21.5 ± 20.2

20.8

LDL-C:HDL-C ratio

0.9 ± 0.4

2.0 ± 0.8

67.3

1.9 ± 0.5

0.5 ± 0.7

18.3

Apo-B:Apo-A1 ratio

0.3 ± 0.1

0.6 ± 0.2

63.3

0.6 ± 0.1

0.2 ± 0.2

21.4

LDL-P size

20.9 ± 0.5

− 0.7 ± 0.6

− 3.6

20.2 ± 0.2

0.0 ± 0.1

0.0